2013 绎 Vol.15 No.8 / 100102 doi: 10.11842/wst.2013.08.012 R271.1 A [1] 4 [2] [3] - Luteinizing Hormone, LH - [4,5] [6] 1.2 58.5% [7] 1 1.1 4~5 [8] [9] - - Follicle -Stimulating Hormone, FSH 2~4 min Thruston RC [10] 2013-10-28 2013-11-19 52 元 2011-CXTD-12 元元 1741
绎 1.3 [11] Terauchi M [12] 237 Spearman Logis 原 tic [13] 200 1.4 - - [14] - [15] [16,17] 1.5 Lampio L [18] 2 7 4 [19] 2.1 1742
2013 绎 Vol.15 No.8 [20] 2.2 [21] [22] [23] 窹 2.3 窹 [24] 2.4 [25] 3 3.1 Liu JH [26] 157 17 茁 - [27] [28] 66 1743
绎 [29,30] 3.2 [31] [32] [33] 4 4.1 [34] - [35] 4.2 [36] [37] 4.3 [38] [39] 88.89% [40] 85.7% [41] 94.74% 4.4 [42] [43] 1744
2013 绎 Vol.15 No.8 4.5 [44] 90% 5 1 Huang K E. Menopause perspectives and treatment of Asian women. SeminReprodMed, 2010, 28(5) 颐 396~403. 2,,,.., 2009, 15(12) 颐 109~111. 3 Pires G N, Tufik S, Andersen M L. Relationship between sleep de 原 privation and anxiety: experimental research perspective. Einstein (Sao Paulo), 2012, 10(4) 颐 519~523. 4,,,.., 2010, 25(25) 颐 3669~3670. 5 Phillips B A, Collop N A, Drake C, et al. Sleep disorders and medical condition in women. Proceedings of the women and sleep workshop, national sleep foundation, Washington DC, March 5-6, 2007. J Womens Health (Larchmt), 2008, 17(7) 颐 1191~1199. 6,,,.., 2010, 26(1) 颐 9~12. 7 Hunter M S, Gupta P, Chedraui P, et al. The international menopause study of climate attitude, temperature (IMS -CAT) and vasomotor symptoms. Climacteric, 2013, 16(1) 颐 8~16. 8 Joffe H, Massler A, Sharkey K. Evaluation and management of sleep disturbance during the menopause transition. Semin Reprod Med, 2010, 28(5) 颐 404~421. 9 Pachman D R, Jones J M, Loprinzi C L. Management of menopauseassociated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health, 2010, 2 颐 123~135. 10 Thurston R C, Santoro N, Matthews K A. Are vasomotor symptoms associated with sleep characteristics among symptomatic midlife women? Comparisons of self -report and objective measures. Menopause, 2012,19(7) 颐 742~748. 11 Salgado-Delgado R, Tapia Osorio A, Saderi N, et al. Disruption of circadian rhythms: a crucial factor in the etiology of depression. Depress Res Treat, 2011 颐 839743. 12 Terauchi M, Hiramitsu S, Akiyoshi M, et al. Associations between anxiety, depression and insomnia in peri - and post -menopausal women. Maturitas, 2012,72(1) 颐 61~65. 13,,,.., 2011, 13(3) 颐 240~241. 14.., 2009, 29(8) 颐 1001~1004. 15 Swick T J. Parkinson s disease and sleep/wake disturbances. Parkinsons Dis, 2012 颐 205471. 16 Conde D M, Costa -Paiva L, Martinez E Z, et al. Bone mineral density in postmenopausal women with and without breast cancer. Rev Assoc Med Bras, 2012, 58(6) 颐 673~678. 17,,,.., 2009, 29(19) 颐 2482~2484. 18 Lampio L, Saaresranta T, Polo O, et al. Subjective sleep in pre 原 menopausal and postmenopausal women during workdays and leisure days: a sleep diary study. Menopause, 2013, 20(6) 颐 655~660. 19.., 2007, 2(9) 颐 520~523. 20,.., 2011, 26(10) 颐 2382~2384. 21,.., 2013, 34(1) 颐 70~71. 22,,,.., 2011, 43(8) 颐 38~39. 23,.. ( ),2013,20(3) 颐 1~23. 24,.., 2010, 27(4) 颐 308~309. 1745
绎 25,.. 2001, 22(5) 颐 45~46. 26 Liu J H, Reape K Z, Hait H I. Synthetic conjugated estrogens -B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol, 2012, 119(1) 颐 78~84. 27 Joffe H, Petrillo L F, Koukopoulos A, et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab, 2011, 96 (7) 颐 E1044~1054. 28.., 2012, 6(23) 颐 51~52. 29 Beral V, Reeves G, Bull D, et al. Million Women Study Collabora 原 tors: Breast cancer risk in relation to the interval between menopause and starting hormone therapy. JNatlCancerInst, 2011, 103(4) 颐 296~305. 30 Phipps A I, Doherty J A, Voigt L F, et al. Long-term Use of Continuous -Combined Estrogen -Progestin Hormone Therapy and Risk of Endometrial Cancer. Cancer Causes Control, 2011, 22(12) 颐 1639~1646. 31 Lo H S, Yang C M, Lo H G, et al. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol, 2010, 33(2) 颐 84~90. 32 Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomni 原 a and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double - blinded, placebo -controlled crossover trial. Am J Obstet Gynecol, 2010, 202(2) 颐 171.e1~171.e11. 33 Ensrud K E, Joffe H, Guthrie K A, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy peri 原 menopausal and postmenopausal women with hot flashes: a random 原 ized controlled trial. Menopause, 2012, 19(8) 颐 848~855. 34. 1., 2011, 17(10) 颐 83. 35. 45., 2010, 8(24) 颐 27~28. 36,. 60., 2012, 4(17) 颐 17~19. 37. 60., 2012, 19(36) 颐 103~104. 38.., 2011, 29(11) 颐 83~84. 39,,.., 2009, 29(6) 颐 475~476. 40. 35., 2008(2) 颐 32. 41,,,.., 2012, 32(7) 颐 701. 42,. 46., 2007, 20(5) 颐 24~25. 43,,,.., 2011, 18(6) 颐 18~20. 44,. 50., 2004, 10(8) 颐 20~34. Current Situation on Sleep Disorders in Menopausal Women He A ixian, Fang Fang (School of Chinese Materia Medica, Beijing University of Chinese Medicine; Laboratory for Basic Chinese Materia Medica and New Drug Research, Beijing 100102, China) Abstract: Sleep disorders are main clinical symptoms in perimenopausal women. The symptoms are difficulty in initiating or maintaining sleep, early morning awakening and so on. These sleep problems had made serious im 鄄 pacts on the quality of women's life during menopausal periods. Menopausal sleep disorders can be caused by changes of serum estrogen levels, vasomotor symptoms, mood disorders and patient's state of disease. This paper presented an overview of inducing factors and current situation of menopausal disorder treatment. Keywords: Perimenopausal period, sleep disorders, inducing factors, drug therapy 1746